DILI: Clinical Trials and Post-Marketing

This course is led by a Hepatologist with extensive experience in clinical assessment of DILI and who published ‘RUCAM’ the widely used causality assessment method of DILI.

参加申し込み

戻る Agenda

SESSION 3: CLINICAL ASPECTS OF DILI

Session Chair(s)

Gaby L. Danan, MD, PHD

Pharmacovigilance Expert

GLD, France

Description
Limitations
Pitfalls
Case studies

Speaker(s)

CLINICAL ASPECTS OF DILI

Gaby L. Danan, MD, PHD

GLD, France

Pharmacovigilance Expert

参加申し込み

DILI: Clinical Trials and Post-Marketing

SESSION 3: CLINICAL ASPECTS OF DILI

Session Chair(s)

Gaby L. Danan, MD, PHD

Speaker(s)

CLINICAL ASPECTS OF DILI

最新情報や機会を逃さないで